Gofen & Glossberg LLC IL boosted its stake in shares of Bristol-Myers Squibb Co. (NYSE:BMY) by 2.9% during the third quarter, according to its most recent filing with the SEC. The firm owned 44,221 shares of the biopharmaceutical company’s stock after buying an additional 1,252 shares during the period. Gofen & Glossberg LLC IL’s holdings in Bristol-Myers Squibb were worth $2,384,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Baxter Bros Inc. purchased a new position in Bristol-Myers Squibb during the second quarter valued at $895,000. Howland Capital Management LLC boosted its position in Bristol-Myers Squibb by 3.2% in the second quarter. Howland Capital Management LLC now owns 38,272 shares of the biopharmaceutical company’s stock valued at $2,815,000 after buying an additional 1,178 shares during the last quarter. Park National Corp OH boosted its position in Bristol-Myers Squibb by 0.6% in the second quarter. Park National Corp OH now owns 56,806 shares of the biopharmaceutical company’s stock valued at $4,178,000 after buying an additional 356 shares during the last quarter. Cullinan Associates Inc. boosted its position in Bristol-Myers Squibb by 17.8% in the second quarter. Cullinan Associates Inc. now owns 585,796 shares of the biopharmaceutical company’s stock valued at $43,085,000 after buying an additional 88,700 shares during the last quarter. Finally, Boltwood Capital Management boosted its position in Bristol-Myers Squibb by 1.7% in the second quarter. Boltwood Capital Management now owns 15,805 shares of the biopharmaceutical company’s stock valued at $1,162,000 after buying an additional 265 shares during the last quarter. 68.84% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Shares of Bristol-Myers Squibb Co. (NYSE:BMY) traded down 0.27% on Tuesday, hitting $56.36. The company’s stock had a trading volume of 9,818,891 shares. The stock has a 50-day moving average price of $52.72 and a 200 day moving average price of $62.87. Bristol-Myers Squibb Co. has a one year low of $49.03 and a one year high of $77.12. The firm has a market cap of $94.19 billion, a price-to-earnings ratio of 28.19 and a beta of 0.90.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 27th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.12. The firm had revenue of $4.83 billion for the quarter, compared to analyst estimates of $4.76 billion. Bristol-Myers Squibb had a net margin of 18.54% and a return on equity of 28.98%. Bristol-Myers Squibb’s quarterly revenue was up 21.0% compared to the same quarter last year. During the same period last year, the company posted $0.39 EPS. Equities research analysts predict that Bristol-Myers Squibb Co. will post $2.85 EPS for the current year.

WARNING: “Gofen & Glossberg LLC IL Raises Stake in Bristol-Myers Squibb Co. (BMY)” was originally published by Financial Market News and is the sole property of of Financial Market News. If you are viewing this piece on another domain, it was stolen and republished in violation of United States and international copyright and trademark laws. The original version of this piece can be accessed at http://www.financial-market-news.com/gofen-glossberg-llc-il-raises-stake-in-bristol-myers-squibb-co-bmy/1209259/.

A number of equities analysts recently commented on BMY shares. SunTrust Banks Inc. cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $86.00 to $68.00 in a report on Friday, August 5th. Zacks Investment Research cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Friday, August 5th. Citigroup Inc. decreased their target price on Bristol-Myers Squibb from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, August 3rd. Piper Jaffray Cos. reaffirmed a “neutral” rating and issued a $65.00 target price (down from $69.00) on shares of Bristol-Myers Squibb in a report on Monday, August 8th. Finally, Deutsche Bank AG decreased their target price on Bristol-Myers Squibb from $68.00 to $62.00 and set a “hold” rating on the stock in a report on Monday, August 8th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $67.51.

In related news, Director Lamberto Andreotti sold 21,600 shares of the firm’s stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $56.87, for a total value of $1,228,392.00. Following the transaction, the director now directly owns 334,499 shares of the company’s stock, valued at approximately $19,022,958.13. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.24% of the stock is currently owned by corporate insiders.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

5 Day Chart for NYSE:BMY

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co. (NYSE:BMY).

Receive News & Ratings for Bristol-Myers Squibb Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co. and related companies with MarketBeat.com's FREE daily email newsletter.